AstraZeneca, Daiichi Sankyo add Datroway to Summit collaboration

AstraZeneca and Daiichi Sankyo plan to test Datroway, also known as datopotamab deruxtecan, with ivonescimab in a Phase III trial for first-line triple-negative breast cancer, according to Thepharmaletter.

The planned study is part of a new collaboration with Summit Therapeutics. Thepharmaletter described AstraZeneca as a UK pharmaceutical major, Daiichi Sankyo as a Japanese drugmaker and Summit Therapeutics as a US biotech company.

Datroway added to collaboration

The collaboration adds Datroway to the work involving AstraZeneca, Daiichi Sankyo and Summit Therapeutics, Thepharmaletter reported. The companies intend to evaluate the treatment alongside ivonescimab in the planned Phase III trial.

The reported focus is first-line triple-negative breast cancer. The announcement identifies a combination of Datroway and ivonescimab as the intended subject of the trial.

Reported development plan

Thepharmaletter reported that Datroway is datopotamab deruxtecan. The publisher said AstraZeneca and Daiichi Sankyo plan the Phase III evaluation under the new collaboration with Summit Therapeutics.

Summit Therapeutics is listed on Nasdaq under the symbol SMMT, according to Thepharmaletter. The announcement brings together the UK pharmaceutical major, the Japanese drugmaker and the US biotech company around the planned breast cancer study.

Industry context

For medical and pharmaceutical sales professionals, the reported event centers on a partnership and a planned Phase III combination trial. The stated trial setting is first-line triple-negative breast cancer, with Datroway to be tested with ivonescimab.

Thepharmaletter’s report frames the development as an addition of Datroway to the collaboration with Summit Therapeutics. No further trial details were provided in the supplied report.